Hong Kong is one of Asia’s fastest-growing medical device markets and an important entry point into the Greater Bay Area. Its strong healthcare system and high demand for advanced technologies attract global manufacturers. To enter the market successfully, companies must understand Hong Kong’s regulatory approach, which differs from the United States, Europe, and other major markets.
Hong Kong uses an administrative control model rather than full statutory regulation. This means that while participation in the system is technically voluntary, hospitals and major distributors require evidence of compliance before accepting products. Companies entering the market must therefore adhere to the rules set out in the Medical Device Administrative Control System (MDACS).
Accurate documentation, compliant labeling, and clear medical device translation are essential. Errors in any of these areas can cause delays, procurement rejection, or restricted product availability. This guide provides a clear overview of how MDACS works and what manufacturers must prepare to achieve successful and compliant medical device registration in Hong Kong.
Regulatory Framework in Hong Kong (MDACS)
Hong Kong medical device regulations are administered under the Medical Device Administrative Control System (MDACS), managed by the Medical Device Division (MDD) of the Department of Health. MDACS was introduced to ensure that medical devices entering the market meet acceptable safety, performance, and quality standards, even though Hong Kong does not yet enforce a full statutory regulatory law for devices.
Although the system is officially voluntary, participation strongly influences market access. Public hospitals, private healthcare groups, and major distributors expect devices to be listed under MDACS before procurement, and listing is frequently a prerequisite for insurance coverage. Consequently, products that are not listed often struggle to gain commercial traction. A listing shows that a manufacturer meets recognised global safety and quality standards, and it enables authorities to monitor product safety and performance after devices enter the market.
MDACS also combines two key forms of regulatory control to safeguard patient safety even in the absence of full statutory regulation.
- Pre-market oversight: Risk-based classification, document evaluation, and listing approval.
- Post-market surveillance: Adverse event reporting, field safety actions, and continuous device monitoring.
Although voluntary today, Hong Kong is moving toward mandatory regulation. MDACS compliance remains the accepted pathway for market access.
Device Classification and Registration Process
To complete medical device registration in Hong Kong, manufacturers must identify the correct risk class and follow a structured listing procedure under MDACS. Risk classification determines the level of regulatory review and documentation required.
Risk-Based Classification (Class I–IV)
The MDACS framework categorizes general medical devices into four classes based on their level of potential risk to patients and users:
| Class | Risk Level | Examples | Listing Requirements |
| Class I | Low Risk | Surgical retractors, bandages | Not eligible for MDACS listing |
| Class II | Low to Moderate Risk | Hypodermic needles, suction pumps | Full MDACS listing recommended |
| Class III | Moderate to High Risk | Lung ventilators, orthopedic implants | Full MDACS listing required |
| Class IV | High Risk | Pacemakers, heart valves | Full MDACS listing required, strong clinical and evidence expected |
Note: In-Vitro Diagnostic (IVD) devices follow a separate classification system (Class A to D). Only Classes B, C, and D are eligible for voluntary listing.
Key Steps in the Listing Process
The MDACS listing pathway follows a precise sequence:
1. Classify the device
Apply official MDACS rules to determine the correct class. The MDD also provides an online classification tool to assist in preliminary assessment.
2. Prepare documentation
Typical requirements include:
- ISO 13485 certification
- Evidence of approval in other regulated markets (e.g., US FDA, CE Mark, Health Canada)
- Technical dossiers and clinical evidence (as applicable to risk class)
- Risk analysis, labeling, and Instructions for Use
- LRP appointment letter and business registration documents
3. Appointment of LRP
Manufacturers outside Hong Kong must appoint a Local Responsible Person (LRP) to manage the application and regulatory communication. The LRP acts as the legal representative for the device and must be a registered entity or individual based in Hong Kong.
4. Submission and Review
All applications must now be submitted electronically through the Medical Device Information System (MDIS). The MDD reviews for completeness and accuracy, and any inconsistencies, particularly in translation, may result in inquiries and delays. The typical review period for a complete submission is about 12 weeks.
5. Listing Approval
Once approved, the device is added to the public “List of Medical Devices,” and a listing number is issued for use on commercial documentation.
Post-Market Requirements and Compliance
Securing your listing is only the first step. Hong Kong medical device regulations place a heavy emphasis on post-market surveillance (PMS) to ensure ongoing patient safety.
Adverse Event Reporting
The LRP is responsible for reporting device-related incidents to the MDD. Reporting deadlines depend on the severity of the event:
- Serious public health threats: report immediately
- Death or serious injury: report within 10 calendar days
- Other reportable events: report within 30 calendar days
Any malfunction, design issue, or use error that leads to harm must be captured and escalated without delay.
Field Safety Corrective Actions (FSCA)
If a manufacturer issues a global recall or safety notice, the LRP must notify the MDD and coordinate the local action plan. This includes tracking which hospitals or distributors received the affected batches and ensuring the product is removed or corrected.
Record-Keeping and Renewal
Compliance does not stop after approval. Companies must maintain distribution records, complaint logs, device history and performance data
Listing certificates are valid for five years and renewed before expiry to avoid delisting and disruption to supply.
The Critical Role of Language and Labeling
Post-market compliance depends on clear communication. Devices for lay users or home use must have labeling and IFUs in both English and Traditional Chinese. Inaccurate or inconsistent translation can lead to:
- User error and patient injury
- Mandatory recalls or safety investigations
- Liability exposure for the manufacturer and the LRP
Regulators expect terminology consistency across all documents; the wording in risk analyses should match that in clinical evidence, labeling, and user manuals. Discrepancies between the original source text and the localized versions are a common cause of regulatory inquiries, audits, and rejections
Conclusion
Hong Kong’s administrative model means that market access depends on demonstrating compliance with the MDACS framework. To succeed, manufacturers must classify devices correctly, prepare robust documentation, appoint a qualified LRP, and maintain strong post-market surveillance. Accurate labeling and high-quality medical device translation are essential to avoiding delays, procurement rejection, or safety risks. Expert localization ensures consistency across technical files, risk documentation, and user instructions, supporting smoother medical device registration in Hong Kong and long-term regulatory success.
EC Innovations provides specialised medical device translation services backed by regulatory expertise. Contact us to ensure accuracy, compliance, and confident entry into Hong Kong medical device regulations.
